Recruitment at The Christ Hospital Health Network Begins for the Pulse-1 Study of VERVE-201
CINCINNATI (September 9, 2026) – The Christ Hospital Health Network is now enrolling patients for a clinical trial evaluating a new gene-editing medicine for adults with high cholesterol. The research is made possible through The Carl and Edyth Lindner Research Center.
VERVE-201, sponsored by Verve Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, is an investigational medicine designed to durably lower triglycerides and cholesterol following a single infusion. VERVE-201 consists of a messenger RNA encoding an adenine base editor and a guide RNA (gRNA) targeting the patient’s genes. The ongoing trial is enrolling adult participants aged 18 to 70 years at The Christ Hospital.
“High cholesterol in patients left unchecked for years is one of the leading risk factors for heart and vascular disease,” said Dean Kereiakes, MD, Chairman of the Heart and Vascular Institute and Principal Investigator for the trial at The Christ Hospital. “Heart disease remains the number one killer of both men and women in the United States. If proven safe and effective, medicines such as VERVE-201 could provide a new treatment option for patients in the future. Through The Carl and Edyth Lindner Research Center, The Christ Hospital is once again leading the way by bringing breakthrough clinical trials with the latest medicines to prevent and treat heart disease in our community for generations to come.”
Pulse-1 is an ongoing open‑label, single‑ascending dose Phase 1b study designed to evaluate the safety, tolerability and pharmacodynamic effects of VERVE-201 in adults with refractory hyperlipidemia, including hypercholesterolemia or hypertriglyceridemia. Participants who qualify for Pulse-1 based on elevated low-density lipoprotein cholesterol (LDL-C) must not be at treatment goal despite taking maximally tolerated background lipid lowering therapy (e.g. statins, PCSK9 inhibitors, ezetimibe, and other cholesterol lowering medications) and have a history of atherosclerotic cardiovascular disease or severe hypercholesterolemia. Participants who qualify based on triglycerides must have a history of severe hypertriglyceridemia that is refractory to standard of care therapies (e.g. fibrates, niacin, fish oil, and other triglyceride-lowering therapies).
About The Christ Hospital Health Network
The Christ Hospital Health Network consists of an acute care hospital located in Mt. Auburn, a remote hospital location in Liberty Township, five ambulatory outpatient centers and dozens of medical offices throughout the region. For 137 years, The Christ Hospital has provided compassionate care to those it serves. Made up of more than 1,300 physicians and more than 7,600 team members, our mission is to improve the health of our community by providing exceptional outc6mes in an affordable way. The Network was recognized by U.S. News & World Report as the #3 hospital in Ohio and named to Newsweek’s World’s Best Hospitals list in 2026.
###
